• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 7.55Adverse events

StudyTreatmentFollow-upOutcomesResult –best treatment
3 RCTs337,338
Level 1+ and 334 Level 1++
Naproxen vs placebo12 weeksDrug-related AEs and SAEsNS
3 RCTs339, 343–345
Level 1+
Total AEsPlacebo (better)
2 RCTs338,341
Level 1+
Dyspepsia AEsPlacebo (better)
1 RCT334
Level 1++
1 or more AEsNS
1 RCT341
Level 1+
12 weeksPercentage of patients with AEsSimilar
1 RCT340
Level 1+
26 weeksPlacebo (better)
3 RCTs337–339
Level 1+
12 weeksHypertension AEsPlacebo (better)
3 RCTs341, 343,345
Level 1+ and 334 Level 1++
NS or similar
1 RCT340
Level 1+
26 weeksPlacebo (better)
1 RCT337
Level 1+
12 weeksGI AEs or nuisance symptomsSimilar
2 RCTs343–345
Level 1+
Placebo (better)
1 RCT340
Level 1+
26 weeksPlacebo (better)
1 RCT342
Level 1+
Naproxen vs nabumetone12 weeksNumber of patients with ≥1 AE; Serious GI AEsSimilar; NS

From: 7, Pharmacological management

Cover of Rheumatoid Arthritis
Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults.
NICE Clinical Guidelines, No. 79.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2009, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.